BioMarker Strategies

BioMarker Strategies is a privately held company located in Redland, Maryland. Founded in the United States, BioMarker Strategies employs 8 individuals. BioMarker Strategies specializes in developing innovative cancer diagnostics. Their flagship product, the SnapPath® Cancer Diagnostics System, enables predictive tests that guide targeted drug development and treatment selection for patients with solid tumors. Through the SnapPath® system, they generate PathMAP® Functional Signaling Profiles, offering a unique approach to biomarker testing. These profiles, derived from live tumor cells, provide highly predictive insights into individual patient responses to targeted therapies. BioMarker Strategies distinguishes itself by automating and standardizing functional ex vivo profiling. Their technology captures dynamic signaling information exclusive to live solid tumor cells, offering a more comprehensive understanding of tumor behavior. This allows for personalized medicine approaches, tailoring treatments to individual patient needs. Businesses interested in collaborating with BioMarker Strategies can explore partnership opportunities. Their technologies, including SnapPath® and PathMAP® Functional Signaling Profiles, are available for research use in preclinical and early clinical settings.